ClinicalTrials.gg
RecruitingNCT05905588Updated Jun 15, 2023

Study of Hydrogen-rich Water Compared With Placebo in Type 2 Diabetes Patients

An interventional study of Hydrogen-rich water and placebo in Type 2 Diabetes, sponsored by Qingdao University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-06-15.

Sponsored by Qingdao University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Aug 2023, 3 years 2 months ago, but the record still lists the study as recruiting.
  • Started Mar 2023; still recruiting 3 years 8 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy and safety of hydrogen-rich water in type 2 diabetes patients.

Read the detailed description

The objective of the study is to evaluate the efficacy and safety of hydrogen-rich water compared with placebo in patients with type 2 diabetes mellitus after 12-week treatment in a randomized, double-blind, placebo-controlled design.

02

Conditions studied

  • Type 2 Diabetes

Keywords

  • type 2 diabetes mellitus
  • hydrogen-rich water
03

In context

Diabetes Mellitus, Type 2

10,371 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,406 are open to participants now.

This study's planned enrollment of 96 is above the median of 80 across 8,350 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Qingdao University is the lead sponsor of 22 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18-75 years old and gender of both sex;
  2. 18.5kg/m2 to 40 kg/m2;
  3. Diagnosed as type 2 diabetes according to the diagnostic criteria of type 2 diabetes established by WHO in 1999;
  4. Patients with type 2 diabetes whose blood glucose is not well controlled after diet control and exercise therapy for more than 3 months;
  5. 7% to 10%, and fasting venous plasma glucose ≤ 15 mmol/L;
  6. Be able to understand the procedures and methods of this clinical study, voluntarily participate in and sign the .

Exclusion criteria

Exclusion Criteria:

  1. Type 1 diabetes, gestational diabetes, or other specific types of diabetes;
  2. Screening for having received anti-diabetic drug therapy within 3 months or receiving continuous anti-diabetic drug therapy at any time before screening for more than 3 months;
  3. History of diabetic ketoacidosis, diabetic hyperglycemic hyperosmolar syndrome, lactic acidosis, diabetic hypoglycemia; or is currently combined with retinopathy, diabetic nephropathy and diabetic neuropathy;
  4. Hyperlipidemia patients with irregular or unstable dose of lipid-lowering drugs;
  5. Chronic gastrointestinal disorders with obvious digestive and absorption disorders, as well as other endocrine diseases, such as hyperthyroidism, hypercortisolism, acromegaly, etc.;
  6. Patients with diseases that may worsen due to intestinal flatulence (such as Roemheld syndrome, severe hernia, intestinal obstruction, intestinal surgery and intestinal ulcers);
  7. Had , cerebrovascular accident or unstable angina in the past 6 months; History of myocardial infarction or had conducted coronary angioplasty or coronary artery bypass graft surgery; Heart failure ( classification Stage III or IV), or left ventricular hypertrophy indicated by ;
  8. Subjects (taking or not taking antihypertensive drugs) had poor blood pressure control (SBP ≥ 160mmhg, or DBP ≥ 100mmhg);
  9. Liver disease, or AST > 2 , or > 2 ULN, and the diagnosis was confirmed within one week;
  10. Patients with renal function impairment (Cr > 1 ULN or Ccr \< 60ml / min) and confirmed by reexamination within one week;
  11. Had in the past 5 years, not including basal cell carcinoma;
  12. History of acute or chronic pancreatitis, or related diseases that are most common cause of acute pancreatitis (such as recurrent cholelithiasis, etc.);
  13. Combined use of drugs that affect glucose metabolism, such as ;
  14. Combined use of Chinese herbal medicine with the effect of regulating blood glucose within 3 months;
  15. Those who have serious diseases and may be in danger of life during treatment and follow-up;
  16. Mental and neurological disorders, unable to correctly express their wishes;
  17. Alcoholics and drug abusers and addicts;
  18. Women of childbearing age are pregnant, breastfeeding, have pregnancy intentions or have a positive pregnancy test (urine HCG or blood HCG), and should not take effective measures during the trial (effective contraceptive measures include sterilization, intrauterine device, oral contraceptive or diaphragm method prescribed by local law);
  19. Patients who have participated in clinical trials of other drugs or medical devices in the past 3 months;
  20. Patients with other diseases that the researchers believe will not be able to evaluate or are unlikely to complete the expected course of treatment and follow-up.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Hydrogen-rich water

    Patients receive hydrogen-rich water.

    Dietary Supplement: Hydrogen-rich water

  • Placebo comparator
    Placebo

    Patients receive placebo.

    Dietary Supplement: placebo

Interventions

  • Dietary supplementHydrogen-rich water

    Patients drink 600mL hydrogen-rich water per day by applying hydrogen-rich water cup (Qingdao Haizhisheng Corp.,LTD, Qingdao, China) for 12 weeks. The dissolved hydrogen concentration is 5 ppm.

  • Dietary supplementplacebo

    Patients drink 600mL tap water per day by applying analogue cup for 12 weeks. This cup has the same appearance as the hydrogen-rich water cup, and the hydrogen-rich water and placebo water were indistinguishable. The dissolved hydrogen concentration is 0 ppm in placebo water.

06

What researchers measure

Primary outcomes

  1. Change in glycosylated hemoglobin (HbA1c)

    The change in HbA1c from baseline to Week 12 in hydrogen-rich water group compared to Placebo.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Change in fasting plasma glucose (FPG)

    The change in FPG from baseline to Week 12 in hydrogen-rich water group compared to Placebo.

    Time frame: Baseline and Week 12

  2. Change in 2h-postprandial plasma glucose (2h-PPG)

    The change in 2h-PPG from baseline to Week 12 in hydrogen-rich water group compared to Placebo.

    Time frame: Baseline and Week 12

  3. Patients with HbA1c <7.0%

    Percentage of patients reaching HbA1c \<7% at Week 12

    Time frame: At Week 12

  4. Patients with HbA1c <6.5%

    Percentage of patients reaching HbA1c \<6.5% at Week 12

    Time frame: At Week 12

  5. Change in fasting plasma insulin

    The change in fasting plasma insulin from baseline to Week 12 in hydrogen-rich water group compared to Placebo.

    Time frame: Baseline and Week 12

  6. Change in insulin sensitivity and beta cell function assessed by the homeostatic model assessment (HOMA)

    The change in HOMA-IR and HOMA-β from baseline to Week 12 in hydrogen-rich water group compared to Placebo.

    Time frame: Baseline and Week 12

  7. Change in serum lipid profile

    The change in total cholesterol, low density lipoprotein, high density lipoprotein, triglycerides from baseline to Week 12 in hydrogen-rich water group compared to Placebo.

    Time frame: Baseline and Week 12

  8. Change in waist circumference

    The change in waist circumference from baseline to Week 12 in hydrogen-rich water group compared to Placebo.

    Time frame: Baseline and Week 12

  9. Change in body weight

    The change in body weight from baseline to Week 12 in hydrogen-rich water group compared to Placebo.

    Time frame: Baseline and Week 12

  10. Change in body mass index (BMI)

    The change in BMI from baseline to Week 12 in hydrogen-rich water group compared to Placebo.

    Time frame: Baseline and Week 12

  11. Change in blood pressure

    The change in blood pressure from baseline to Week 12 in hydrogen-rich water group compared to Placebo.

    Time frame: Baseline and Week 12

  12. Change in oxidative stress index and inflammatory index

    Serum MDA and SOD, TNF-α, IL-6 quantifications were conducted using commercial kits from baseline to Week 12.

    Time frame: Baseline and Week 12

  13. Number of participants with adverse events as a measure of safety and tolerability

    Number of participants with adverse events from baseline to Week 12.

    Time frame: Baseline to Week 12

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Aug 2023, 5 months after the start.

Of 2,066 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 5 months is below that.

Counting every sponsor, half of 2,243 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2023
First posted
Jun 15, 2023
StartActual
Mar 1, 2023
Primary completionEst.
Aug 31, 2023
CompletionEst.
Aug 31, 2023
Last update
Jun 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05905588
Lead sponsor
Qingdao University
Collaborators
Qingdao Hiser Medical Group
Responsible party
Tongshang Ni (Lecturer, Qingdao University) — Principal investigator
First posted
Jun 15, 2023
Start date
Mar 1, 2023
Primary completion
Aug 31, 2023 (estimated)
Completion
Aug 31, 2023 (estimated)
Last update
Jun 15, 2023

Study contacts

Tongshang Ni, Ph.D
Contact
neetongshang@126.com
+86 17354605382
Tongshang Ni, Ph.D
principal investigator · Qingdao Universtiy

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hydrogen Rich Water

Start the discussion